AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca announced updated Phase 3 trial data of its Covid-19 vaccine, addressing concerns from a U.S. health agency about outdated interim data.

AstraZeneca Says Vaccine 76% Effective in Updated Trial Data and Plans to Seek U.S. Approval

After teaming up with Oxford University, AstraZeneca produced a safe and effective Covid-19 vaccine in just nine months, a huge achievement that will help end the pandemic. But a series of missteps along the way has led to scathing criticism from policymakers and health officials, tarnishing the company's image as a hero of the coronavirus era.

How a series of unforced errors tarnished AstraZeneca's image

AstraZeneca has updated its US COVID-19 vaccine trial results following concerns from Dr. Anthony Fauci and a panel of experts that the drugmaker had presented outdated data. The updated results, released Thursday, showed AstraZeneca's shot was 76% effective at protecting against symptomatic COVID-19, 15 days after the second dose of the two-dose vaccine. The company had said on Monday that the vaccine was 79% effective in the trial, which involved more than 32,000 people.

AstraZeneca revises down its vaccine efficacy in a huge US trial, from 79% to 76%, following concerns from Fauci and other experts that the results were outdated

NextEra Energy

A plunging market would be the opportune time to buy these superior stocks.

3 Perfect Stocks to Buy If the Stock Market Crashes

AstraZeneca PLC (LON:AZN) has published the primary results on Coronavirus (COVID-19) vaccine trials, which were consistent with the interim data published on Monday. The FTSE 100 pharma company said the jab showed 76% efficacy in preventing symptoms, 100% efficacy against severe or critical disease and hospitalisation and 85% efficacy against symptoms in participants aged 65 years and over.

AstraZeneca publishes primary COVID-19 vaccine trial results consistent with Monday data

AstraZeneca Plc (NASDAQ: AZN) on Wednesday issued a fresh update of its phase three trial data for the COVID-19 vaccine after a U.S. health agency earlier this week questioned the accuracy of the trial data. What Happened: The British drugmaker's latest update claims the vaccine developed with Oxford University is 76% effective in protecting against symptomatic cases of the virus, from 79% efficacy reported on Monday.

AstraZeneca Revises COVID-19 Vaccine Efficacy To 76% After Controversy

The new result reiterates the vaccine is 100% effective in preventing severe disease and hospitalization.

Revised U.S. Trials Numbers Show AstraZeneca Vaccine Is 76% Effective Against Symptomatic Covid-19

AstraZeneca PLC, which has been under fire for the accuracy of its data, on Wednesday night announced updated Phase 3 trial data of its coronavirus vaccine, saying it's 76% effective at preventing symptomatic COVID-19.

AstraZeneca now says its COVID-19 vaccine is 76% effective

AstraZeneca issued updated phase three trial data for its Covid-19 vaccine on Wednesday after facing criticism earlier this week over a preliminary report from its U.S. study.

AstraZeneca issues updated Phase 3 trial data for its Covid vaccine after facing criticism

WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday, March 22, 2021. These results have been presented to the independent Data Safety Monitoring Board. The primary analysis is pre-specified in the protocol and will be the basis for a regulatory submission for Emergency Use Authorization to the US Food and Drug Adm

AZD1222 US Phase III Primary Analysis Confirms Safety and Efficacy

Inspection is fresh sign of breakdown in relations between Brussels and Anglo-Swedish vaccine supplier

AstraZeneca plant inspected by Italian police at EU's request

Dr. Anthony Fauci, President Joe Biden's chief medical advisor, again sought to reassure Americans that AstraZeneca's still-experimental COVID-19 vaccine is a strong candidate even though the drug maker reportedly miscommunicated findings from a clinical trial earlier this week.

Fauci insists that AstraZeneca's COVID-19 vaccine candidate is ‘good' after issue with information in company's press release

AstraZeneca will likely release a modified statement regarding its Covid-19 vaccine, White House Chief Medical Advisor Dr. Anthony Fauci said Wednesday.

Fauci says AstraZeneca will likely issue modified statement on Covid vaccine

Los Angeles, California--(Newsfile Corp. - March 24, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive...

MONDAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

AstraZeneca's data misstep is just the latest example in a series of blunders by the company that could impact people's willingness to take the vaccine.

AstraZeneca missteps threaten to further erode trust in Covid vaccine as company seeks U.S. approval

BioNTech SE

Johnson & Johnson

Moderna

Novavax

Pfizer

Viatris

This question has multiple right answers.

Which COVID Vaccine Stock Is the Best Pick?

NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against AstraZeneca plc ("AstraZeneca" or the "Company") (NASDAQ: AZN) and certain of its officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 21-cv-00825, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise, acquired AstraZeneca securities between May 21, 2020 and November 20, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AstraZeneca plc of Class Action Lawsuit and Upcoming Deadline - AZN

AstraZeneca has defended its use of coronavirus vaccine data after US authorities suggested some results from a large American-led trial may have been based on "outdated information".

AstraZeneca defends COVID vaccine trial data against US claims of possible 'outdated information'

LOS ANGELES--(BUSINESS WIRE)---- $AZN #AZN--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AstraZeneca PLC

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AstraZeneca PLC and Encourages Investors with Losses of $100,000 to Contact the Firm

Investors will have to wait for the final results from a U.S. based clinical trial.

AstraZeneca's Vaccine Data May Not Be as Good as It First Appeared

The consequences of being irrationally exuberant about the current state of the SARS-Co-V-2 pandemic has the potential to lead to much more than a financial downturn; it has the potential to lead to an unimaginable continued loss of life.

AstraZeneca, Data Collection, And Covid-19 Irrational Exuberance

White House Chief Medical Advisor Dr. Anthony Fauci has commented on the latest AstraZeneca plc (NASDAQ: AZN) coronavirus vaccine controversy, noting the company's Monday press release contains some falsehoods but that shouldn't take away from the efficacy of the vaccine.  The numbers published Monday were based on a pre-specified interim analysis with a Feb. 17 data cutoff, AstraZeneca said in a press release late Tuesday morning.

Fauci Reacts To AstraZeneca Coronavirus Data, Says British Vaccine Developer Made 'Unforced Error'

Snowflake

Snowflake Inc (NYSE: SNOW) shares are trading higher after UBS initiated coverage on the stock with a Buy rating and a price target of $275 per share. Snowflake is a data lake, warehousing, and sharing company that came public in 2020.

What's Happening With SNOW Stock And AZN Stock Tuesday?

The global case tally for the coronavirus-borne illness COVID-19 crept closer to 124 million on Tuesday, as U.S. health officials raised concerns about results from a trial of AstraZeneca PLC's vaccine less than a day after the data were released.

Coronavirus Update: Global case tally for COVID-19 nears 124 million as U.S. health experts question AstraZeneca trial data

In a rare public rebuke, the top US infectious disease doctor is criticizing the pharma company AstraZeneca for statements it recently made about its coronavirus vaccine. Dr. Anthony Fauci said on Tuesday that AstraZeneca's Monday press release about its COVID-19 vaccine "wasn't completely accurate."

News for AstraZeneca Stock (AZN)